Carfilzomib
- BNF:
- Not listed
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- August 2017
Comments
RED:
- NICE TA657: for previously treated multiple myeloma (replaces NICE TA457). (Decision date - December 2020).
- NICE TA695: Carfilzomib with dexamethasone and
lenalidomide for previously treated multiple myeloma. (Decision date - May 2021).
Do Not Prescribe (DNP):
- NICE TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma. Terminated appraisal. (Decision date - December 2022)
NHS England drug. To be used in line with NHSE commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again